Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocular Therapeutix, Inc. - Common Stock
(NQ:
OCUL
)
12.58
+0.15 (+1.21%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocular Therapeutix, Inc. - Common Stock
< Previous
1
2
Next >
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
November 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
November 07, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
October 24, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
September 27, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 22, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
August 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
July 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
June 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
June 01, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
May 09, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
May 03, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
April 26, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 14, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
February 22, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
February 11, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
January 18, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 04, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
December 06, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
November 15, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
November 09, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
November 08, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
November 05, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021
November 01, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
October 29, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
October 28, 2021
From
Ocular Therapeutix
Via
Business Wire
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
October 22, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
